- DRUG DISCOVERY SERVICES
ABOUT MOLECULAR SENSING & BSI TECHNOLOGY
Molecular Sensing, Inc. (MSI) is commercializing Back-Scattering Interferometry (BSI), the world’s first label-free, conformation-sensitive detection technology for biophysical characterization of small molecule interactions with complex drug targets. This includes integral membrane proteins and biochemically intractable target binding assays in native-like, free-solution environments — no tags or tethering.
Conformational change is the hallmark of protein dynamics and are intimately related to protein function. BSI detects binding-induced target conformational change with high specificity and sensitivity. It allows unlabeled binding affinity measurement, target engagement verification and mechanism-of-action elucidation in a single assay platform, vital to informing pharmacology and medicinal chemistry drug discovery efforts.
MSI currently offers the TruBind™ BSI System 100 and TruBind Assay Services to pharmaceutical companies.
Please send us an email or give us a call at (615) 938-7050 in North America or +49 (171) 760-4450 in Europe to find out how MSI can help accelerate your assay development and screening efforts.
- Review of Recent Publications Featuring Binding Data Produced by MSIBy MSI on January 26, 2016
- Conformation-Sensitive Assay Detection for Accelerated Drug Discovery ResearchBy MSI on February 10, 2015
- Using BSI to Investigate Positive Allosteric Modulators of the M4 ReceptorBy MSI on September 3, 2014